Glenmark Pharma US arm to launch sodium phosphate injection, begin distribution in April

Glenmark Pharmaceuticals Ltd. on Friday, February 27, said its US subsidiary is launching the sodium phosphates injection USP in the 15 mM P/5 ml, 45 mM p/15 ml and 150 mM P/5 ml, single-dose vials.The company said the single-dose vial is bioequivalent and therapeutically equivalent to the reference listed drug of the injection in the 45 mM p/15 ml of Hospira Inc.

These 14 mM P/5 ml and 150 mM P/50 ml presentations are expected to have the same therapeutic effect as that of the listed drug product upon which the US Food and Drug Administration (USFDA) relied as the basis of safety and effectiveness, the company said.
Glenmark will begin its distribution in April 2026.As per the IQVIA sales data for the 12 months ending December 2025, the injection’s single-dose vials market achieved annual sales of around $66.8 million.

Earlier this month, the company’s executive director and global chief financial officer Anurag Mantra told CNBC-TV18 that the pharma firm is expecting its core business margins to expand by 100 to 150 basis points in the financial year 2-27 to settle around 23%.

He also said the company is on track to become debt-free by March, adding that the pharma firm is already in a significantly positive net cash position.

Shares of Glenmark are trading 0.3% higher on Friday at ₹2,130.1. The stock has gained 5% so far in the first two months of the year.

Also Read: GAIL shares have multiple worries ahead, Kotak warns projecting 14% downside